.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01A_AlkylatingAgents.L01AB01_Busulfan.Busulfan .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01A_AlkylatingAgents.L01AB01_Busulfan.Busulfan| name: | Busulfan |
| ATC code: | L01AB01 | route: | intravenous |
| n-compartments | 2 |
Busulfan is an alkylating agent that is used primarily as a chemotherapy drug for conditioning regimens prior to hematopoietic stem cell transplantation, especially in chronic myelogenous leukemia and other hematological malignancies. It is approved and in clinical use today.
Pharmacokinetic parameters reported for adult patients undergoing hematopoietic stem cell transplantation; intravenous administration.
Takahashi, T, et al., & Al-Kofahi, M (2023). Population Pharmacokinetic Model of Intravenous Busulfan in Hematopoietic Cell Transplantation: Systematic Review and Comparative Simulations. Clinical pharmacokinetics 62(7) 955–968. DOI:10.1007/s40262-023-01275-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/37415003
Wu, X, et al., & Huang, X (2017). Population pharmacokinetics analysis of intravenous busulfan in Chinese patients undergoing hematopoietic stem cell transplantation. Clinical and experimental pharmacology & physiology 44(5) 529–538. DOI:10.1111/1440-1681.12735 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28135768
Ishiwata, Y, et al., & Yasuhara, M (2018). Population Pharmacokinetics of Intravenous Busulfan in Japanese Pediatric Patients With Primary Immunodeficiency Diseases. Journal of clinical pharmacology 58(3) 327–331. DOI:10.1002/jcph.1027 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29077206